Unknown PHASE1 INTERVENTIONAL 1-arm NCT02779439

Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation (R3ACT)

Therapeutic Infusion of Partially HLA-matched Third Party Donor-derived Virus- and Fungus Specific T-lymphocytes in Patients With Active Viral or Fungal Infection Post-allogeneic Stem Cell or Solid Organ Transplantation

Sponsor: University of Sydney

Conditions Adenovirus CMV Infection EBV

Interventions Virus specific CTLs

Updated 6 times since 2017 Last updated: Jul 20, 2016 Started: Jan 31, 2013 Primary completion: Dec 31, 2017 Completion: Mar 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02779439, this PHASE1 trial focuses on Adenovirus and CMV Infection and remains ongoing. Sponsored by University of Sydney, it has been updated 6 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Aug 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sydney

Data source: University of Sydney

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia